Nature's TRAIL--on a path to cancer immunotherapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Immunity

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1074-7613(02)00502-2PMID 12530970
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax

  2002cited by this paper
• T cells require TRAIL for optimal graft-versus-tumor activity

  2002cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development

  2002cited by this paper
• TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

  2002cited by this paper
• TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO.

  2002cited by this paper
• Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice1

  2002cited by this paper
• Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach.

  2001cited by this paper
• Relative resistance of fresh isolates of melanoma to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.

  2001cited by this paper
• The potential of TRAIL for cancer chemotherapy

  2001cited by this paper
• Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling

  2001cited by this paper
• How melanoma cells evade trail-induced apoptosis

  2001cited by this paper
• Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

  2001cited by this paper
• Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells

  2001cited by this paper
• In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity

  2001cited by this paper
• Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity

  2001cited by this paper
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

  2001cited by this paper
• Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

  2001cited by this paper
• Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis1

  2001cited by this paper
• Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis

  2001cited by this paper
• Antiviral response by natural killer cells through TRAIL gene induction by IFN–α/β 

  2001cited by this paper
• KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death.

  2000cited by this paper
• TRAIL receptor-2 signals apoptosis through FADD and caspase-8

  2000cited by this paper
• Perforin-Mediated Cytotoxicity Is Critical for Surveillance of Spontaneous Lymphoma

  2000cited by this paper
• Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression

  2000cited by this paper
• Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs

  1999cited by this paper
• To die or not to die—the quest of the TRAIL receptors

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL

  1999cited by this paper
• Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail)

  1999cited by this paper
• Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells

  1998cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper

• International validation of a natural-killer-cell-based model to predict recurrence-free survival in hepatocellular carcinoma.

  2025cites this paper
• Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells

  2025cites this paper
• Bioorthogonal click chemistry-mediated conjugation of an anti-DR4 antibody to gold nanorods enhances its pro-apoptotic activity under near infra-red-light stimulation

  2025cites this paper
• Immunological landscape of colorectal cancer: tumor microenvironment, cellular players and immunotherapeutic opportunities

  2025cites this paper
• Transcriptomic Profiling of the Tumor Microenvironment in High-Grade Serous Carcinoma: A Pilot Study of Morphologic and Molecular Distinctions Between Classic and SET Patterns

  2025cites this paper
• Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value.

  2025cites this paper
• DMC-siERCC2 hybrid nanoparticle enhances TRAIL sensitivity by inducing cell cycle arrest for glioblastoma treatment.

  2024cites this paper
• TRIAL-based combination therapies in cancers.

  2024cites this paper
• Gintonin-Enriched Panax ginseng Extract Fraction Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis through DR4/5 Upregulation

  2024cites this paper
• PP2A negatively regulates NK cell T-bet expression and anti-tumor effector function.

  2024cites this paper
• TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling

  2024cites this paper
• ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression

  2023cites this paper
• The role of p53 in anti-tumor immunity and response to immunotherapy

  2023cites this paper
• Recent advancements to engineer mesenchymal stem cells and their extracellular vesicles for targeting and destroying tumors.

  2023cites this paper
• TRAIL promotes the polarization of human macrophages toward a proinflammatory M1 phenotype and is associated with increased survival in cancer patients with high tumor macrophage content

  2023cites this paper
• The therapeutic effects of mesenchymal stem cells and their secretome on oral squamous cell carcinoma.

  2023cites this paper
• Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome

  2022cites this paper
• Differential early diagnosis of benign versus malignant lung cancer using systematic pathway flux analysis of peripheral blood leukocytes

  2022cites this paper
• miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.

  2022cites this paper
• TRAIL in the Treatment of Cancer: From Soluble Cytokine to Nanosystems

  2022cites this paper
• Interleukin-1 alpha and high mobility group box-1 secretion in polyinosinic:polycytidylic-induced colorectal cancer cells occur via RIPK1-dependent mechanism and participate in tumourigenesis

  2022cites this paper
• Facile discovery of a therapeutic agent for NK-mediated synergistic antitumor effects using a patient-derived 3D platform.

  2021cites this paper
• Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis

  2021cites this paper
• Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling

  2021cites this paper
• Transcriptome Analysis of Large to Giant Congenital Melanocytic Nevus Reveals Cell Cycle Arrest and Immune Evasion: Identifying Potential Targets for Treatment

  2021cites this paper
• Preventive Cancer Vaccination by P5 HER-2/neo Derived Peptide-pulsed Peripheral Blood Mononuclear Cells in Mouse Model of Breast Cancer.

  2021cites this paper
• Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer

  2020cites this paper
• Natural killers or ILC1s? That is the question.

  2020cites this paper
• Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells

  2020cites this paper
• Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers

  2020cites this paper
• Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system

  2020cites this paper
• PBRM1 and the glycosylphosphatidylinositol biosynthetic pathway promote tumor killing mediated by MHC-unrestricted cytotoxic lymphocytes

  2020cites this paper
• Molecular mechanisms of natural compounds in cell death induction and sensitization to chemotherapeutic drugs in lung cancer

  2019cites this paper
• The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression

  2019cites this paper
• Andrographolide Enhances TRAIL-Induced Apoptosis via p53-Mediated Death Receptors Up-Regulation and Suppression of the NF-кB Pathway in Bladder Cancer Cells

  2019cites this paper
• The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations

  2019cites this paper
• Monocyte-Macrophage Differentiation Suppresses the Expression of Proapoptotic Receptors to Apo2L/TRAIL and Increases Resistance to TRAIL-Induced Apoptosis

  2019cites this paper
• Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.

  2019cites this paper
• Nanoscale metal-organic frameworks and coordination polymers as theranostic platforms for cancer treatment

  2019cites this paper
• An in-silico study examining the induction of apoptosis by Cryptotanshinone in metastatic melanoma cell lines

  2018cites this paper
• Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor1

  2018cites this paper
• Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.

  2018cites this paper
• Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function

  2018cites this paper
• Bid Cleavage and TRAIL Sensitivity in Urothelial Cell Carcinoma of the Bladder

  2018cites this paper
• Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration

  2018cites this paper
• NK Cell-Based Therapies

  2018cites this paper
• Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer

  2018cites this paper
• Exosomes derived from TRAIL‐engineered mesenchymal stem cells with effective anti‐tumor activity in a mouse melanoma model

  2018cites this paper
• Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review

  2018cites this paper
• 28 Targeting TRAIL Receptors with Genetically-Engineered CD 34 + Hematopoietic Stem Cells

  2018cites this paper
• Virus Infection and Death Receptor-Mediated Apoptosis

  2017cites this paper
• N-terminal gelsolin fragment potentiates TRAIL mediated death in resistant hepatoma cells

  2017cites this paper
• NK Cell Subsets in Health and Disease: New Developments

  2017influential citation
• Engineering of Micro- to Nanostructured 3D-Printed Drug-Releasing Titanium Implants for Enhanced Osseointegration and Localized Delivery of Anticancer Drugs.

  2017cites this paper
• Investigating the role of NK cells in allogeneic haematopoietic stem cell transplantation

  2017cites this paper
• The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5

  2017cites this paper
• Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.

  2017cites this paper
• The role of macrophages in the differentiation process of ureteral polyps

  2017cites this paper
• Implication of 4 EBP 1 protein dephosphorylation and accumulation in 1 pancreatic cancer cell death induced by combined gemcitabine and 2 TRAIL 3 4

  2017cites this paper
• Digitoxin increases sensitivity of glioma stem cells to TRAIL-mediated apoptosis.

  2017cites this paper
• 6.02 – Cancer Immunotherapy

  2017cites this paper
• Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy

  2017cites this paper
• Identification, characterization and bioactivity of tumor necrosis factor (TNF)‐related apoptosis‐inducing ligand from Equus caballus

  2017cites this paper
• Immune modulation by dendritic-cell-based cancer vaccines

  2017cites this paper
• Clinical Applications of Natural Killer Cells

  2017influential citation
• Migratory Capacity Subsets with Distinct Responsiveness and CD27 Dissects Mature NK Cells into Two

  2017cites this paper
• Donor Natural Killer Cells and Their Therapeutic Potential in Allogeneic Hematopoietic Stem Cell Transplantation

  2017cites this paper
• TRAIL gene expression analysis in multiple sclerosis patients

  2016cites this paper
• Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells

  2016cites this paper
• Assessment of combined vaccination and immune modulation as an anti-tumour therapy

  2016cites this paper
• Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis

  2016cites this paper
• Type 1 Innate Lymphoid Cell Biology: Lessons Learnt from Natural Killer Cells

  2016cites this paper
• Fluorinated dendrimer for TRAIL gene therapy in cancer treatment.

  2016cites this paper
• Autosomal Dominant Polycystic Disease is Associated with Depressed Levels of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.

  2016cites this paper
• Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells

  2016cites this paper
• Choline kinase inhibitors synergize with TRAIL in the treatment of colorectal tumors and overcomes TRAIL resistance

  2016cites this paper
• Regulation of Human Innate Immune Cells by Inflammatory Lipids

  2016cites this paper
• Dependency of Ly49 Recognition on Anchor Residues of Peptide Bound to MHC-I

  2015cites this paper
• Eliminating acute myeloid leukemia stem cells by targeting the niche microenviromnent: Co-inhibition of TNF/IL1-JNK and NF-kappaB

  2015cites this paper
• Downregulation of SNAIL sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis by regulating the NF-κB pathway.

  2015cites this paper
• Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.

  2015cites this paper
• Systems Biology Strategy Reveals PKCδ is Key for Sensitizing TRAIL-Resistant Human Fibrosarcoma

  2015cites this paper
• « Une nouvelle cellule dendritique impliquée dans l'immunité anti-tumorale / Interferon- producing killer dendritic cells (IKDC) »

  2015cites this paper
• NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy

  2015cites this paper
• Glycogen synthase kinase-3β regulates tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis via the NF-κB pathway in hepatocellular carcinoma.

  2015cites this paper
• Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.

  2015cites this paper
• Kinetic Monte Carlo study of the type1/type 2 choice in apoptosis elucidates selective killing of cancer cells under death ligand induction

  2015cites this paper
• Etude de l'impact de la leptine sur le statut oxydatif et inflammatoire du tissu mammaire : approche expérimentale in vitro et in vivo - Mise en oeuvre de la technique de détection par fluorescence native.

  2015cites this paper
• La leptine : un modulateur de l’activité des cellules Natural Killer ?

  2015cites this paper
• Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5

  2015cites this paper
• Clinical chorioamnionitis at term V: umbilical cord plasma cytokine profile in the context of a systemic maternal inflammatory response

  2015cites this paper
• Relationship between tumour necrosis factor‐related apoptosis inducing ligand (TRAIL) and vascular endothelial growth factor in human multiple myeloma patients

  2015cites this paper
• Regulatory T cells in haematopoietic stem cell transplantation

  2014cites this paper
• Structurally engineered anodic alumina nanotubes as nano-carriers for delivery of anticancer therapeutics.

  2014cites this paper
• Role of serum TRAIL level and TRAIL apoptosis gene expression in multiple sclerosis and relation to brain atrophy.

  2014cites this paper
• Local tumour ablative therapies: opportunities for maximising immune engagement and activation.

  2014cites this paper
• THE CRITICAL ROLE OF PI3K-AKT-mTOR PATHWAY FOR IL-15 INDUCED NK CELL EFFECTOR RESPONSES

  2014cites this paper
• Maternal plasma soluble TRAIL is decreased in preeclampsia

  2014cites this paper
• DAPK2 is a novel modulator of TRAIL-induced apoptosis

  2014cites this paper
• Genetically engineered donor T cells to optimize graft‐versus‐tumor effects across MHC barriers

  2014cites this paper